Compare CIGI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIGI | RYTM |
|---|---|---|
| Founded | 1972 | 2008 |
| Country | Canada | United States |
| Employees | N/A | 414 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.2B |
| IPO Year | 1995 | 2017 |
| Metric | CIGI | RYTM |
|---|---|---|
| Price | $94.02 | $88.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $176.25 | $131.14 |
| AVG Volume (30 Days) | 305.5K | ★ 713.2K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.28 | $55.34 |
| Revenue Next Year | $8.30 | $86.06 |
| P/E Ratio | $57.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $90.93 | $58.71 |
| 52 Week High | $171.20 | $122.20 |
| Indicator | CIGI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 47.71 |
| Support Level | N/A | $87.19 |
| Resistance Level | $120.37 | $92.17 |
| Average True Range (ATR) | 4.26 | 4.91 |
| MACD | -1.01 | 0.15 |
| Stochastic Oscillator | 8.97 | 41.94 |
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are Commercial Real Estate, Engineering and Investment Management. Maximum revenue for the company is generated from its Commercial Real Estate segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, and others. Geographically, the company generates maximum revenue from the United States followed by Canada, Euro currency countries, Australia, the United Kingdom, Poland, China, India, and other regions.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.